For patients with radiologically isolated syndrome (RIS) predictive of multiple sclerosis (MS), teriflunomide reduced the risk of a demyelinating event over a 2-year period in a phase 3 trial.
Scotch Plains, NJ (PRWEB) November 10, 2022 Anderson Publishing, Ltd., publishers of Applied Radiology, a leading clinical-review publication and website